Ipilimumab (Yervoy) is an antibody inhibitor that blocks the inhibitory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells, with immune-activating properties. Used for the treatment of unresectable or metastatic melanoma, this antibody exhibits antitumor activity.

Objective: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. Concentrations: 0, 0.5, 5.0, and 50 μg/mL. Incubation Time: 10-14 days. Method: hPBMC were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi) or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell line or Burkitt's lymphoma cell line (Daudi).

Objective: To investigate whether Ipilimumab and PD-1 antibody enhance the ability of T cells to control the outgrowth of EBV-induced lymphomas. Formulation: PBS. Dosages: 100 μg, three times weekly

伊匹单抗

Human

Immobilized Human CTLA-4 Protein (His) (TMPY-04348) at 10 μg/mL (100 μL/well) can bind Ipilimumab. The EC50 is 0.88 ng/mL.

Monoclonal

Unconjugated